278 related articles for article (PubMed ID: 8070218)
1. Ifosfamide clinical pharmacokinetics.
Wagner T
Clin Pharmacokinet; 1994 Jun; 26(6):439-56. PubMed ID: 8070218
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
3. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites.
Woodland C; Ito S; Granvil CP; Wainer IW; Klein J; Koren G
Life Sci; 2000 Nov; 68(1):109-17. PubMed ID: 11132240
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo.
Springate JE
J Appl Toxicol; 1997; 17(1):75-9. PubMed ID: 9048231
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide metabolism and pharmacokinetics (review).
Kaijser GP; Beijnen JH; Bult A; Underberg WJ
Anticancer Res; 1994; 14(2A):517-31. PubMed ID: 8017856
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, mesna, and nephrotoxicity in children.
Skinner R; Sharkey IM; Pearson AD; Craft AW
J Clin Oncol; 1993 Jan; 11(1):173-90. PubMed ID: 8418231
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide pharmacokinetics.
Lewis LD
Invest New Drugs; 1991 Nov; 9(4):305-11. PubMed ID: 1804803
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide and mesna.
Schoenike SE; Dana WJ
Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of ifosfamide.
Furlanut M; Franceschi L
Oncology; 2003; 65 Suppl 2():2-6. PubMed ID: 14586139
[TBL] [Abstract][Full Text] [Related]
10. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Kerbusch T; de Kraker J; Keizer HJ; van Putten JW; Groen HJ; Jansen RL; Schellens JH; Beijnen JH
Clin Pharmacokinet; 2001 Jan; 40(1):41-62. PubMed ID: 11236809
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
13. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
[TBL] [Abstract][Full Text] [Related]
14. Neurological toxicity of ifosfamide.
Nicolao P; Giometto B
Oncology; 2003; 65 Suppl 2():11-6. PubMed ID: 14586141
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide--pharmacologic overview.
Sarosy G
Semin Oncol; 1989 Feb; 16(1 Suppl 3):2-8. PubMed ID: 2649983
[TBL] [Abstract][Full Text] [Related]
16. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R
Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956
[TBL] [Abstract][Full Text] [Related]
17. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide.
Dubourg L; Michoudet C; Cochat P; Baverel G
J Am Soc Nephrol; 2001 Aug; 12(8):1615-1623. PubMed ID: 11461933
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells.
Springate J; Chan K; Lu H; Davies S; Taub M
In Vitro Cell Dev Biol Anim; 1999 Jun; 35(6):314-7. PubMed ID: 10476917
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide and mesna: effects on the Na/H exchanger activity in renal epithelial cells in culture (LLC-PK1).
Mohrmann M; Küpper N; Schönfield B; Brandis M
Ren Physiol Biochem; 1995; 18(3):118-27. PubMed ID: 7542792
[TBL] [Abstract][Full Text] [Related]
20. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Sloderbach A; Górska A; Sikorska M; Misiura K; Hładoń B
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1235-53. PubMed ID: 24379264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
